Psyence Biomedical Ltd
NASDAQ:PBM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (11.4), the stock would be worth $-19.29 (303% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.6 | $9.49 |
0%
|
| Industry Average | 11.4 | $-19.29 |
-303%
|
| Country Average | 14.5 | $-24.57 |
-359%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
P
|
Psyence Biomedical Ltd
NASDAQ:PBM
|
9.7m USD | -5.6 | 3.3 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
267.2B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 3 537.2 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.7B ZAR | 14.4 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.3B USD | -18 026.5 | 38 496.8 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
57.8B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
35.8B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
33.1B EUR | 67.3 | 175.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
37.9B USD | -742.9 | -3 482 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.2B ZAR | 17.7 | 7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.6 |
| Median | 14.5 |
| 70th Percentile | 20.6 |
| Max | 3 794.4 |
Other Multiples
Psyence Biomedical Ltd
Glance View
Psyence Biomedical Ltd is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
